Global High-Priority Regulatory Events — May 13, 2026

13-05-2026

Semnur Pharmaceuticals reported a sharply widened net loss of $4,576 thousand for Q1 2026 compared to $665 thousand in Q1 2025, driven by R&D expenses surging to $1,266 thousand (up 577% YoY) and G&A expenses to $3,310 thousand (up 592% YoY), resulting in total operating expenses of $4,576 thousand (up 588% YoY). Total assets increased to $1,969 thousand from $1,346 thousand at December 31, 2025, with cash rising to $103 thousand from $20 thousand, but liabilities grew to $27,295 thousand from $22,096 thousand, largely due to a related party loan increase to $16,915 thousand, deepening stockholders' deficit to $25,326 thousand. While financing activities provided $2,753 thousand net cash (up from $394 thousand), operating cash use intensified to $2,670 thousand from $399 thousand.

• · Net cash used in operating activities: $2,670 thousand in Q1 2026 vs $399 thousand in Q1 2025.
• · Net cash provided by financing activities: $2,753 thousand in Q1 2026 (primarily $3,503 thousand from related party loans, offset by $750 thousand promissory note repayment).
• · Stock-based compensation: $1,484 thousand in Q1 2026 vs $92 thousand in Q1 2025.
• · Property and equipment, net remained flat at $750 thousand.
• · Net loss per share: $(0.02) basic and diluted in Q1 2026 vs $(0.01) in Q1 2025.

13-05-2026

The Board of Directors of CyberTech Systems and Software Limited approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an un-modified auditor's opinion. They recommended a final dividend of ₹4 per equity share of ₹10 face value for FY 2025-26 and approved a buyback of up to 8,50,000 equity shares at ₹170 per share, aggregating to ₹14,45,00,000, representing 2.73% of total paid-up equity share capital. A Buyback Committee was formed, with record date fixed as May 29, 2026.

• · Record date for buyback: Friday, May 29, 2026.
• · Pre-buyback shareholding pattern as on May 08, 2026 (Annexure IV).
• · Appointment of M/s. Desai Associates as Internal Auditors for FY 2026-27.
• · Auditor's report provides un-modified opinion on consolidated financial results.

13-05-2026

Nuvve Holding Corp. entered into a Securities Exchange and Omnibus Amendment Agreement effective May 12, 2026, with Holders including Five Narrow Lane, L.P., to exchange all outstanding Existing Warrants for Exchange Shares representing 55% of the Common Stock issuable upon exercise and terminate the $25 million ELOC Facility originally dated December 1, 2025. In exchange for waiving Additional Investment Rights, the Holders consented to amendments of the 2025 Purchase Agreement and Series A Certificate of Designations, which require stockholder approval by July 27, 2026; failure to obtain approval could terminate the agreement. While this reduces potential future dilution from warrants, AIRs, and the ELOC, it results in immediate issuance of new shares, diluting existing shareholders.

• · Agreement relies on Section 3(a)(9) exemption from registration under the Securities Act
• · Holders hold a majority of outstanding Series A Preferred Stock and will vote in favor of the Certificate of Designations Amendment
• · Company to hold special stockholder meeting no later than July 27, 2026, for approval
• · Mutual release of all claims related to Existing Warrants
• · Company to reimburse Holders' reasonable costs and expenses on Closing Date

13-05-2026

LIC Housing Finance reported FY26 Profit After Tax of Rs.5595.15 Cr, up 3% YoY, with Q4 FY26 PAT at Rs.1497.41 Cr, up 9% YoY, and total disbursements of Rs.66544 Cr, up 4% YoY, while outstanding portfolio grew 4% to Rs.320707 Cr. However, net interest margins declined to 2.68% for FY26 from 2.73% and to 2.80% in Q4 FY26 from 2.85%, Q4 revenue from operations fell 1% to Rs.7194.34 Cr, ROE dropped to 14% from 16%, and ROA to 1.78% from 1.83%. Stage 3 EAD improved to 2.16% from 2.47%, with ECL provisions down to Rs.4569 Cr from Rs.4899 Cr.

• · LIC shareholding at 45.24% as of March 2026.
• · Board proposed dividend of 500% i.e. Rs.10.00 per share.
• · Capital Adequacy Ratio (Total) 24.22% as of March 2026.
• · Online Loan approvals during FY26: Rs.6530 Cr.

13-05-2026

NMF SLF I, Inc. reported a net increase in net assets from operations of $1,648 for Q1 2026, down sharply 92% YoY from $21,842, driven by total investment income declining 8% YoY to $34,505 amid lower interest income, partially offset by reduced expenses, though marred by $21,297 unrealized depreciation versus only $383 prior year. Net assets fell 2% QoQ to $957,927 with NAV per share dropping to $10.01 from $10.23, while net borrowings improved to $500,650 from $567,179. Distributions of $23,552 were declared, contributing to a net decrease in net assets of $21,904 for the quarter.

• · Net borrowings decreased 12% QoQ to $500,650 from $567,179.
• · Cash and cash equivalents declined to $21,645 from $25,285 QoQ.
• · Proceeds from sales and paydowns of investments: $60,932 in Q1 2026 vs $54,808 YoY.
• · Purchases of investments: $24,845 in Q1 2026 vs $27,718 YoY.

13-05-2026

HF Sinclair Corporation terminated the employment of Atanas Atanasov as Executive Vice President and Chief Financial Officer, effective immediately on May 13, 2026, after he had been on leave since February 24, 2026. Vivek Garg, the Company's Vice President, Chief Accounting Officer and Controller, has served as acting CFO since February 24, 2026. Atanasov may be eligible for severance benefits under the Company's Severance Pay Plan if conditions are met.

• · Atanasov on leave since February 24, 2026, as reported in Form 10-K filed February 27, 2026.
• · Severance Pay Plan details in Proxy Statement filed March 31, 2026.

13-05-2026

Bogota Financial Corp. reported net income of $705,946 for Q1 2026, down 3.4% YoY from $730,947, despite net interest income rising 23.2% YoY to $4,426,491 driven by lower interest expense. Total assets declined 3.0% QoQ to $877.2M, with deposits dropping 7.9% QoQ to $600.9M and loans net decreasing 1.4% QoQ to $639.4M, while stockholders' equity increased 0.8% QoQ to $142.1M. Non-interest income fell sharply 63.9% YoY to $321K, primarily due to lower bank-owned life insurance gains.

• · Provision for credit losses of $50,000 in Q1 2026 vs recovery of $80,000 in Q1 2025.
• · EPS basic and diluted remained flat at $0.06 YoY.
• · Short-term FHLB advances increased to $58.5M from $20M QoQ.

13-05-2026

BRILLIANT N.E.V. CORP. reported no revenues for the three months ended October 31, 2025, with a net loss of $498, a slight 0.4% improvement from $500 in the year-ago period due to marginally lower general and administrative expenses ($498 vs $500). Cash used in operating activities decreased significantly to $201 from $599 YoY, but the cash balance declined quarter-over-quarter to $5,547 from $5,748 amid ongoing operational cash burn. Stockholders' deficit worsened slightly to $(43,796) from $(43,298) QoQ.

• · Total current assets declined to $5,547 from $5,847 QoQ.
• · Prepaid expenses decreased to $0 from $99 QoQ.
• · Loans from related party remained flat at $49,145.
• · Common stock par value $0.001, authorized 345,000,000 shares.

13-05-2026

Principal Credit Real Estate Income Trust reported net income of $1,889 thousand for Q1 2026, a turnaround from a $971 thousand net loss in Q1 2025, driven by total revenue growth of 59% YoY to $6,734 thousand and lower expenses. However, investments in loans receivable declined 6% QoQ to $353,158 thousand from $377,308 thousand, leading to total assets decreasing 4% QoQ to $383,964 thousand. Shareholders' equity improved significantly, rising 120% QoQ to $6,682 thousand, while loans payable fell 7% QoQ to $258,646 thousand.

• · Operating cash flow improved to $2,676 thousand in Q1 2026 from $(305) thousand used in Q1 2025.
• · Net cash from investing activities $23,759 thousand in Q1 2026 (driven by $25,000 thousand loan repayments) vs $(75,512) thousand used in Q1 2025.
• · Goldman Repurchase Agreement: $142,927 thousand outstanding, fair value $142,979 thousand, available capacity $107,073 thousand.
• · Citi Repurchase Agreement: $115,575 thousand outstanding, fair value $115,667 thousand, available capacity $134,425 thousand.
• · Cash and cash equivalents increased to $20,700 thousand as of Mar 31, 2026 from $10,547 thousand as of Dec 31, 2025.

13-05-2026

Radhagobind Commercial Limited, under Corporate Insolvency Resolution Process (CIRP) as ordered by NCLT Kolkata Bench, has intimated stock exchanges about its 8th Committee of Creditors (COC) meeting scheduled for May 15, 2026, at 5:00 PM in Kannur, Kerala, via physical and video conferencing modes. Chaired by Resolution Professional Adv. Najeeb T P, the agenda includes CIRP progress on a reserved NCLT extension order, approval of a legal consultant for resolution plan due diligence, review of CIRP costs to date, interim finance from creditors, and other related matters. This ongoing insolvency process highlights significant financial distress with no resolution achieved after multiple COC meetings.

• · NCLT orders: CP (IB)/71/KB/2025 dated 30.10.2025 (Interim RP appointment) and IA (I.B.C)/90(KB)2026 dated 27-01-2026 (RP appointment)
• · Scrip Codes: BSE 030070, CSE 539673
• · Meeting venue: Baithussalam, Balankinar, Kattampally Road, Near Indus Motors Maruthi Service Centre, Kannur 670011, Kerala
• · Contact: najetpip@gmail.com, radhagobindcirp2025@gmail.com, Mob: 91-9846603236

13-05-2026

For the three months ended March 31, 2026, Lincoln National Life Insurance Co reported total revenues of $4,641, up 17.9% YoY from $3,937, driven by higher net investment income (+9.4%) and realized gains of $366 versus a $248 loss. However, expenses rose to $4,786 (up 5.7% YoY), resulting in a net loss of $93 (improved from $439 loss YoY) and comprehensive income of $63; total assets declined 2.4% QoQ to $422,397 while stockholder's equity fell 1.7% QoQ to $11,784.

• · Insurance premiums declined 1.5% YoY to $1,602 from $1,627.
• · Realized gain of $366 in Q1 2026 vs loss of $248 in Q1 2025.
• · Market risk benefit loss increased to $711 from $618 YoY.
• · Net cash provided by operating activities $307 vs used $257 YoY.
• · Cash and invested cash decreased $2,241 QoQ to $5,705.

13-05-2026

Momentus Inc. reported service revenue of $3,215 thousand for Q1 2026, a 899% YoY increase from $322 thousand, driving gross profit to $1,817 thousand. However, operating expenses rose 62% to $10,509 thousand, resulting in an operating loss of $8,692 thousand and net loss of $9,480 thousand, wider than the prior year's net loss of $6,172 thousand. Share-based compensation remained elevated at $322 thousand, matching total stock compensation expense.

• · Options outstanding stable at 2,424 as of March 31, 2026, with weighted-average exercise price $632.86.
• · RSUs outstanding increased to 126,643 from 42,604 as of December 31, 2025.
• · Total dilutive securities rose to 2,359,385 in Q1 2026 from 289,409 in Q1 2025.
• · Cash paid for interest $65 thousand; operating lease payments $419 thousand in Q1 2026.

13-05-2026

Astronics Corp (ATROB) reported robust Q1 2026 financial results with sales increasing 12.0% YoY to $230,619 thousand, gross profit rising 23.5% to $75,133 thousand, operating income more than doubling by 107.3% to $27,230 thousand, and net income surging 168.0% to $25,540 thousand. However, net cash provided by operating activities declined 48.6% YoY to $10,606 thousand due to working capital outflows including higher accounts receivable and inventories, leading to a $6,313 thousand decrease in cash and equivalents to $11,867 thousand, exacerbated by elevated capital expenditures of $11,160 thousand. Total assets grew 5.7% to $747,143 thousand from year-end 2025, supported by equity expansion to $161,702 thousand.

• · Accounts Receivable increased $12,352 thousand from December 31, 2025 to April 4, 2026, using $13,420 thousand in operating cash flow YoY.
• · Inventories rose $15,085 thousand quarter-over-quarter, contributing to $16,404 thousand YoY cash outflow.
• · Long-term Debt stable at approximately $334,885 thousand as of April 4, 2026.
• · Basic EPS $0.71 vs $0.27 YoY; Diluted EPS $0.67 vs $0.26 YoY.
• · Interest Paid $2,668 thousand in Q1 2026.

13-05-2026

For the three months ended March 31, 2026, New Mountain Guardian IV Income Fund reported total investment income of $11,427 thousand, up 14% YoY from $10,032 thousand, driven by higher interest income, with net investment income increasing 23% YoY to $8,925 thousand. However, net unrealized depreciation of $7,363 thousand (vs $843 thousand YoY) and realized losses of $264 thousand resulted in a net operations increase of only $1,298 thousand, down 80% YoY from $6,389 thousand, leading to members' capital declining to $501,846 thousand (down 1.5% QoQ) and NAV per unit falling to $9.79 from $9.94 QoQ. Distributions declared totaled $8,865 thousand, up from $7,394 thousand YoY.

• · Cash and cash equivalents declined to $24,395 thousand from $35,000 thousand QoQ.
• · Total liabilities increased to $14,080 thousand from $11,287 thousand QoQ.
• · Net cash used in operating activities improved to $1,210 thousand used from $9,765 thousand used YoY.
• · First Lien investments showed net unrealized depreciation of $4,041 thousand in Q1 2026.
• · Investment purchases totaled $25,682 thousand in Q1 2026, with proceeds from sales/paydowns at $16,452 thousand.

13-05-2026

Revenues were nearly flat, up 0.2% YoY to $435,775 for the three months ended April 4, 2026, while the net loss widened significantly to $10,685 from $3,258 in the prior year period due to higher general and administrative expenses ($49,199 vs. $40,600) and depreciation ($21,256 vs. $18,568). Total assets grew 7.6% QoQ to $1,612,555 driven by acquisitions and higher cash ($28,212 vs. $12,397), but long-term debt increased to $459,997 from $317,279 and common shareholders' equity declined to $122,876 from $143,052. Operating cash flow deteriorated to $(17,978) used from $(4,391) used YoY amid higher capex and business purchases.

• · Accounts receivable, net increased to $393,085 from $385,470 QoQ.
• · Goodwill rose to $125,785 from $98,723 QoQ due to business combinations.
• · Capital expenditures on equipment $25,090 and land/buildings $12,162.
• · Shares repurchased for treasury $13,305.
• · Dividend $0.030 per share, total $1,212.

13-05-2026

Kennedy Lewis Capital Co's Q1 2026 10-Q shows total investment income of $30,682,777, up 33% YoY from $23,097,252, with net investment income rising 39% YoY to $17,080,995, contributing to a net increase in net assets from operations of $16,871,658, up 84% YoY. However, total investments at fair value declined 1.2% QoQ to $1,096,362,224 from $1,109,977,047 amid net unrealized depreciation of $457,982, and NAV per Class I share edged down to $20.00 from $20.04 QoQ. Total net assets grew 5.4% QoQ to $744,822,375, supported by share issuances and reinvestments.

• · Secured Credit Facility remained flat at $412,500,000 QoQ.
• · Cash and cash equivalents decreased to $5,496,329 from $60,216,576 QoQ; restricted cash increased to $44,269,851 from $32,440,987.
• · Net cash used in operating activities was $40,902,980 for Q1 2026.
• · Common shares outstanding increased to 37,246,308 from 35,262,120 QoQ.

13-05-2026

For the three months ended March 31, 2026, Strategic Student & Senior Housing Trust, Inc. reported leasing and related revenues of $10,223,590, up 13.1% YoY from $9,040,180, leading to income from operations of $949,286, a 203.7% increase from $312,614. However, the company recorded a net loss of $302,308, an improvement from $1,042,092 YoY but still negative, with property operating expenses rising 8.8% to $6,887,268 and total equity declining to $7,004,057 from $7,687,989 at December 31, 2025. Cash from operations strengthened to $1,489,242, up 68.2% YoY.

• · Net cash provided by operating activities increased to $1,489,242 in Q1 2026 from $885,605 in Q1 2025.
• · Debt, net decreased to $101,947,470 as of March 31, 2026 from $102,406,080 at December 31, 2025.
• · Accumulated depreciation increased to $41,728,809 from $40,271,844 QoQ.
• · Cash and cash equivalents rose to $4,440,994 from $3,010,009 QoQ.

13-05-2026

GROOVY COMPANY, INC. (GROO) filed an 8-K on May 13, 2026, covering Items 4.01 (changes in certifying accountant), 5.02 (departure or election of directors/officers), 5.03 (amendment to Articles of Incorporation), 8.01 (other events), and 9.01 (exhibits). Exhibit 3.1 details the Amendment to the Articles of Incorporation. No financial metrics or performance changes were disclosed.

• · Filing Items: 4.01 (Accountant Changes), 5.02 (Officer/Director Changes), 5.03 (Articles Amendment), 8.01 (Other Events), 9.01 (Exhibits)
• · Subcategory: Accountant Changes

13-05-2026

CareView Communications Inc reported Q1 2026 total revenues of $2,191,342, down 2% YoY from $2,239,347, driven by a 17% decline in sales-based software bundle revenue to $935,654 despite growth in subscription-based revenue (+3% to $1,017,483) and equipment packages (+97% to $238,205). Operating income improved to $30,843 from a $134,710 loss YoY due to 9% lower operating expenses, resulting in a smaller net loss of $756,200; however, cash flows from operations turned negative at $126,166 from $267,881 YoY, reducing cash to $1,411,435.

• · Accrued interest payable increased to $23,698,264 as of Mar 31, 2026 from $22,896,139 at Dec 31, 2025.
• · Stock-based compensation expense of $150,302 in Q1 2026.
• · Contract liabilities balance decreased to $2,618,960 end Q1 2026 from $3,158,474 end Q1 2025.

13-05-2026

UTG Inc's Q1 2026 net income attributable to common shareholders surged 81% YoY to $23,436,868 from $12,952,643, propelled by total net investment gains of $31,762,259 versus $17,266,251 prior year, leading to total revenue of $36,493,614, up 67% YoY. Total assets expanded 6% QoQ to $521,392,599 from $491,368,581, with cash and equivalents rising 53% to $46,771,832. However, premiums and policy fees fell 6% YoY to $1,796,689, fixed maturities declined 1% QoQ to $72,174,265, and net cash from operations remained negative at $(2,598,871).

• · Gross unrealized losses on fixed maturities increased to $2,270,006 as of March 31, 2026 from $1,949,786 at December 31, 2025.
• · Net cash used in operating activities improved to $(2,598,871) from $(3,255,211) YoY.
• · Basic EPS increased to $7.46 from $4.10 YoY.
• · Share repurchases: Treasury shares acquired and retired for $195,773.

13-05-2026

Kadant Inc reported revenue of $281,505 thousand for the three months ended April 4, 2026, up 17.7% YoY from $239,210 thousand, driven by higher sales, while operating income rose 12.7% to $40,109 thousand. However, net cash provided by operating activities declined 4.0% to $21,916 thousand, comprehensive income attributable to Kadant fell to $22,053 thousand from $34,007 thousand due to a $3,486 thousand foreign currency translation loss, and diluted EPS growth slowed to 5.9% at $2.16. Total assets remained stable at $1,714,652 thousand.

• · Interest expense increased to $4,484 thousand from $3,822 thousand YoY.
• · Cost of revenue rose 20.1% YoY to $154,802 thousand.
• · Cash and cash equivalents decreased to $117,025 thousand from $119,551 thousand at January 3, 2026.

13-05-2026

Rare Element Resources Ltd reported a narrowed net loss of $2,133 for Q1 2026 compared to $2,395 in Q1 2025, driven by lower operating expenses of $2,340 versus $2,672 YoY, while cash and total assets surged to $47,141 and $52,627 respectively from $19,315 and $24,120 at year-end 2025 due to a $30,478 rights offering. However, net cash used in operating activities increased to $2,725 from $2,269 YoY, and the accumulated deficit grew to $183,123 from $180,990. Shares outstanding rose to 645,368,390 from 516,134,712 QoQ amid the financing.

• · Exploration and evaluation expenses: $1,719 in Q1 2026 vs $1,877 in Q1 2025
• · Corporate administration expenses: $580 in Q1 2026 vs $750 in Q1 2025
• · Non-operating income: $207 in Q1 2026 vs $277 in Q1 2025
• · Accumulated deficit: $183,123 as of March 31, 2026

13-05-2026

For Q1 2026, Sensus Healthcare reported revenues of $3.4M, down 59% YoY from $8.3M, primarily due to a 75% drop in point-in-time product revenue to $1.7M, resulting in gross profit falling 77% to $1.0M and operating loss widening to $4.4M from $2.6M. Operating expenses decreased 24% YoY to $5.3M, driven by cuts in selling/marketing (-21%) and R&D (-39%), leading to a net loss of $2.6M similar to prior year aided by a $1.6M tax benefit. Cash and equivalents declined 17% QoQ to $18.3M amid $3.8M used in operations.

• · Remaining deferred revenue as of Mar 31 2026: $0.6M total ($0.1M product, $0.6M service).
• · Inventories increased to $16.5M from $14.6M QoQ.
• · Net cash used in operating activities: $3.8M in Q1 2026 vs $2.7M in Q1 2025.
• · Tax benefit of $1.6M in Q1 2026 vs provision of $0.1M in Q1 2025.

13-05-2026

Spruce Biosciences reported a narrowed net loss of $12,266 for Q1 2026 versus $14,041 in Q1 2025, driven by a 17% reduction in total operating expenses to $11,987, primarily from a 30% cut in R&D expenses to $7,575, though G&A expenses rose 21% to $4,412. Cash and cash equivalents increased to $54,080 from $48,906 QoQ, supported by $14,146 in debt proceeds, but stockholders' equity declined to $34,648 from $42,516 amid higher liabilities including $6,464 in debt and $3,938 warrant liability. Cash burn from operations improved to $8,732 used from $12,727 YoY.

• · Weighted-average shares outstanding: 1,372,084 in Q1 2026 vs 586,142 in Q1 2025.
• · Debt, total: $6,464 as of March 31, 2026 (none as of Dec 31, 2025).
• · Net cash provided by financing activities: $13,916 in Q1 2026.

13-05-2026

The Canary Litecoin ETF reported a QoQ decline in net assets to $6,216,656 as of March 31, 2026, from $6,960,107 at December 31, 2025, driven by a net decrease from operations of $(2,666,242) due to unrealized depreciation of $(2,118,115) and realized losses of $(531,647) on Litecoin investments. While shares outstanding increased 27% to 470,000 amid $2,646,019 in shares sold, NAV per share fell sharply 30% to $13.23. Litecoin holdings grew in quantity to 115,005 from 90,747, but fair value dropped 11% to $6,221,839 reflecting cryptocurrency price depreciation.

• · Paid-in capital increased to $10,738,775 from $8,815,984, while accumulated deficit deepened to $(4,522,119) from $(1,855,877).
• · 40,000 shares redeemed across Q1 2026 at average prices declining from $16.54 in January to $13.28 in March.
• · Investments in Litecoin at cost: $10,182,602 as of March 31, 2026.

13-05-2026

Pismo Coast Village Inc reported results for the three and six months ended March 31, 2026, with quarterly revenue increasing 13% YoY to $2,223,000 from $1,966,000, driven by 15% growth in resort operations to $2,031,000, while achieving operating income of $64,000 versus a $187,000 loss prior year. For the six months, revenue rose 13% to $4,536,000, with net income of $111,000 versus a $160,000 loss, but retail operations declined 4% to $279,000 and property lease income fell 11% to $101,000, resulting in a modest six-month operating loss of $14,000. Total assets grew to $31,649,000 from $30,529,000 at September 30, 2025.

• · Net cash provided by operating activities was $1,543,000 for six months ended March 31, 2026, slightly down from $1,545,000 prior year.
• · Capital expenditures of $213,000 in six months ended March 31, 2026, up from $113,000.
• · Property and equipment, net decreased slightly to $16,573,000 from $16,588,000.
• · Customer deposits increased to $3,977,000 from $2,596,000.

13-05-2026

Stereotaxis, Inc. reported Q1 2026 total revenue of $6,291 thousand, down 15.8% YoY from $7,472 thousand, with systems revenue declining 32.8% to $1,319 thousand and disposables, service, and accessories down 9.7% to $4,972 thousand. Operating loss widened slightly to $5,981 thousand from $5,929 thousand, despite a 2.2% reduction in operating expenses to $9,775 thousand. However, cash and equivalents increased 8.9% QoQ to $14,616 thousand, bolstered by $4,716 thousand in net financing proceeds from stock issuance.

• · Current deferred revenue increased to $6,541 thousand from $5,675 thousand QoQ.
• · Contingent consideration increased to $10,374 thousand total ($5,266 current + $5,108 long-term) from $9,618 thousand.
• · Stock-based compensation expense was $2,110 thousand in Q1 2026, down from $2,535 thousand in Q1 2025.
• · Net cash used in operating activities increased to $3,442 thousand from $1,779 thousand YoY.

13-05-2026

Embassy Bancorp, Inc. reported Q1 2026 net income of $3,739 thousand (up 29.5% YoY from $2,887 thousand) and basic/diluted EPS of $0.50 (up from $0.38), driven by net interest income growth of 16.4% YoY to $11,441 thousand. Total assets increased 2.3% QoQ to $1,841,972 thousand, with deposits up 2.5% to $1,681,828 thousand and loans up 0.4% to $1,283,791 thousand. However, comprehensive loss was $168 thousand (vs. $5,642 thousand income YoY) due to $3,907 thousand net unrealized loss on securities, resulting in stockholders' equity declining 2.2% QoQ to $124,807 thousand; non-interest expenses also rose 9.5% YoY to $7,559 thousand.

• · Provision for credit losses: $20 thousand in Q1 2026 (down from $47 thousand YoY)
• · Net cash provided by operating activities: $4,831 thousand in Q1 2026 (up from $2,684 thousand YoY)
• · Treasury stock purchases: 150,000 shares for $2,959 thousand in Q1 2026
• · Cash and cash equivalents: $141,833 thousand as of March 31, 2026 (up $28,974 thousand QoQ)

13-05-2026

OMEROS CORP reported net income of $56.1M for Q1 2026, a significant turnaround from a $33.5M net loss in Q1 2025, driven primarily by a $73.1M non-cash gain on financial instruments and $9.9M in product sales versus none prior year; R&D expenses declined 44% YoY to $13.4M while SG&A rose 20% to $13.4M. However, the company posted an operating loss of $17.4M (improved from $35.0M YoY), cash and equivalents dropped sharply to $1.9M from $9.7M QoQ amid $15.0M net cash used in operations, and total assets fell 12% QoQ to $286.2M.

• · 2026 Notes fully repaid at maturity on February 15, 2026.
• · OMIDRIA royalty obligation principal payments of $4.7M in Q1 2026.
• · Weighted-average diluted shares: 90,116,352 in Q1 2026 vs 58,056,357 in Q1 2025.
• · Cash paid for interest: $5.6M in Q1 2026.

13-05-2026

TELA Bio reported Q1 2026 revenue of $19,059, up 3% YoY from $18,520, with gross profit remaining nearly flat at $12,520. However, net loss widened to $12,273 from $11,264 YoY due to higher operating expenses ($23,046 vs $22,984) and interest expense, while cash and equivalents fell to $39,541 from $50,845 QoQ and stockholders' equity shifted to a $5,201 deficit from $6,313.

• · Inventory excess and obsolescence charge increased to $935 in Q1 2026 from $630 in Q1 2025.
• · Proceeds from the sale of product line were $309 in Q1 2026 vs $170 in Q1 2025.
• · Accounts receivable, net decreased to $9,715 as of March 31, 2026 from $10,347 as of December 31, 2025.

13-05-2026

AmpliTech Group reported Q1 2026 revenue of $5,349,446, up 48.6% YoY from $3,599,099, driven by strong growth in Manufacturing and Engineering (AmpliTech Inc. and Specialty Microwave) to $3,283,537 (+233%), while Distribution (Spectrum) declined 21% to $2,065,909. Gross profit more than doubled to $2,566,866, but operating expenses rose 36% to $4,185,974, resulting in a narrower net loss of $1,521,707 (improved 17.3% from $1,840,521) or $(0.06) per share. The company raised $9.8M net via rights and direct offerings, boosting stockholders' equity to $48,360,710, though cash used in operations increased to $3,140,825.

• · R&D expenses declined 32% YoY to $503,046, with $128,429 on 5G and $374,617 on MMIC design.
• · Net cash used in investing activities $6,580,128 mainly due to marketable securities.
• · Cash and cash equivalents ended at $11,807,881, up slightly from $11,685,395.

13-05-2026

Allegro MicroSystems, Inc. (Nasdaq: ALGM) appointed Robert J. Willett as an independent director to its Board, effective May 13, 2026. Mr. Willett brings over two decades of experience in industrial technology and automation, including 14 years as CEO of Cognex Corporation where he scaled the business and drove organic growth. The appointment is viewed positively by Chairman Joseph Martin for adding expertise in sensors, industrial automation, and capital deployment to support Allegro's expansion in automotive, AI data centers, and robotics.

• · Mr. Willett holds a bachelor’s degree from Brown University and an MBA from Yale University.
• · Contact: jhoover@allegromicro.com

13-05-2026

Jack in the Box Inc. reported Q2 FY2026 same-store sales decline of 3.8% YoY (systemwide), with total revenues down 4.3% to $254.3 million from $265.7 million, diluted EPS from continuing operations at $0.65 versus $1.09, Restaurant-Level Margin falling to 16.4% ($15.5 million) from 19.6% ($18.7 million), and Adjusted EBITDA decreasing to $51.3 million from $61.5 million. Franchise-Level Margin dropped to 37.9% ($60.5 million) from 40.0% ($68.3 million), though restaurant count remained flat at 2,128 with 9 openings and 9 closures. Management highlighted improving trends into Q3 under interim CEO Mark King, with updated FY2026 guidance for low single-digit SSS decline and Franchise-Level Margin of $265-275 million.

• · Del Taco losses from discontinued operations $2.3 million in Q2 FY2026 vs. $162.9 million prior year.
• · SG&A expense $26.4 million, down $1.8 million YoY.
• · FY2026 guidance: Company-Owned Restaurant Level Margin ~17%, SG&A $115-125 million, Adjusted EBITDA $225-235 million, restaurant count 2,050-2,100.
• · No share repurchases in Q2; dividend discontinued.
• · Actively pursuing refinancing of 2019-1 Class A-2-II Notes (repay Aug 2026) and 2022-1 Class A-2-I Notes (Feb 2027).

13-05-2026

AudioEye, Inc.'s DEF 14A proxy statement details non-employee director compensation for fiscal year 2025, consisting solely of equity awards (RSUs) with grant date fair values ranging from $13,187 for Anthony Coelho to $176,691 for Lead Independent Director Jamil Tahir; no cash fees were paid. Stockholders approved the executive compensation program with 99% support in the 2025 Say-on-Pay vote. There are no related party transactions requiring disclosure, and executive officers include Kelly Georgevich (CEO, CFO, Secretary) and David Moradi (Executive Chairman, Chief Product Officer).

• · Annual RSUs vest on the earlier of one year from grant or prior to next annual meeting; settled on 3rd anniversary, change in control, or year after death.
• · Quarterly RSUs vest on grant date; same settlement terms.
• · As of Dec 31, 2025: Anthony Coelho held 63,736 vested but unsettled RSUs; Dr. Fleming held 20,797 vested and 5,667 unvested RSUs; Jamil Tahir held 102,904 vested and 8,500 unvested RSUs; James Hawkins held 3,486 vested and 5,667 unvested RSUs.
• · Grants in 2025: May 23 - 5,667 RSUs each to Hawkins/Fleming, 8,500 to Tahir; March 3 - 1,270 prorated RSUs to Hawkins.
• · No material nonpublic information considered in equity award timing; anti-hedging policy in place.

13-05-2026

Applied Optoelectronics, Inc. (AAOI) entered into a lease agreement dated May 8, 2026, with Hightower Phase I Owner, LLC for a 163,930 rentable square foot building (Hightower Business Park - Phase I – Building 1) at 6000 McHard Road, Houston, Texas 77053, plus an adjacent 3.34 acre unimproved Reserve Tract 4, for general industrial/warehouse and light manufacturing use over a 123-month term. Basic rent for the building is $0 for months 1-3, then escalates from $104,915.20 monthly ($0.64 per sq ft) in months 4-15 to $146,127.30 ($0.89 per sq ft) in months 112-123; Reserve Tract 4 rent starts at $6,680 monthly from month 4, rising to $9,303.99. No early performance metrics are available, but the lease includes a $391,613.18 security deposit and anticipated substantial completion around November 1, 2026.

• · Commencement Date: Earliest of Tenant occupancy for business, Substantial Completion of Work (per Exhibit D), or date Work would have been Substantially Completed absent Tenant Delays.
• · Estimated Delivery Date: November 1, 2026; Outside Delivery Date: January 1, 2027 (extended for Tenant Delays or Force Majeure).
• · Tenant’s Proportionate Share: 100%.
• · Permitted Use: General industrial/warehouse for light manufacturing, receiving, storing, shipping, and wholesale sales.
• · Exclusive rights: 24/7 use of loading facilities, trash removal area, and designated parking areas.

13-05-2026

On May 13, 2026, Las Vegas Sands Corp. completed a public offering of $500 million aggregate principal amount of 5.300% Senior Notes due 2031 and $500 million of 5.650% Senior Notes due 2033, issued under indentures with U.S. Bank Trust Company as trustee. The company plans to use net proceeds along with cash on hand to fully redeem its outstanding $1.0 billion 3.500% Senior Notes due August 2026, pay related fees, and for general corporate purposes. The new notes are unsecured senior obligations ranking equally with other unsubordinated debt but carry no subsidiary guarantees and feature higher interest rates than the redeemed notes.

• · 2031 Notes mature May 15, 2031; interest payable semi-annually on May 15 and November 15, commencing November 15, 2026.
• · 2033 Notes mature May 18, 2033; interest payable semi-annually on May 18 and November 18, commencing November 18, 2026.
• · Notes redeemable prior to par call dates (April 15, 2031 for 2031 Notes; March 18, 2033 for 2033 Notes) at greater of discounted present value or 100% principal plus accrued interest.
• · Indenture covenants limit liens, sale-leaseback transactions, and consolidations/mergers/disposals.

13-05-2026

Dermata Therapeutics reported a narrowed net loss of $1,847,706 for Q1 2026, improving 19.8% YoY from $2,303,587 in Q1 2025, primarily due to a 70.1% reduction in R&D expenses to $383,724, though SG&A expenses rose 45.7% to $1,542,658. Cash and equivalents decreased $576,696 QoQ to $6,945,282 as of March 31, 2026 from $7,521,978 at December 31, 2025, amid higher net cash used in operations of $2,479,718 versus $1,934,066 YoY. Stockholders' equity increased to $6,413,003, supported by $1,994,051 net proceeds from ATM common stock sales.

• · Weighted-average shares outstanding increased to 3,858,921 in Q1 2026 from 515,465 in Q1 2025, improving EPS to $(0.48) from $(4.47).
• · New inventory of $93,091 (raw materials) as of March 31, 2026.
• · 5,424,598 warrants outstanding as of March 31, 2026.
• · Net cash provided by financing activities $1,903,022 in Q1 2026, down significantly from $8,491,764 in Q1 2025.

13-05-2026

The Canary Staked SUI ETF (SUIS) launched on February 17, 2026, reported net assets of $24,184,075 as of March 31, 2026, with 1,060,000 shares outstanding at a NAV of $22.82 per share, driven by $26,459,775 in capital inflows from shares sold. The fund generated $43,073 in staking income, resulting in net investment income of $21,339 after $21,734 sponsor fees; however, it recorded a net operational loss of $2,275,700 due to $2,295,737 unrealized depreciation and a $1,302 realized loss on SUI investments. Investments in SUI totaled $24,200,340 at fair value (27,492,860 SUI tokens), compared to a cost basis of $26,496,077.

• · Payable to Sponsor: $16,265
• · Fund inception date: February 17, 2026 (beginning net assets: $0)

13-05-2026

Auburn National Bancorporation reported Q1 2026 net earnings of $2,198 thousand, up 43.7% YoY from $1,530 thousand, supported by 9.7% YoY growth in net interest income to $7,733 thousand and 19.5% increase in noninterest income, while noninterest expense remained flat at $5,901 thousand. Loans grew 3.0% QoQ to $582,040 thousand and deposits rose 0.9% to $931,109 thousand, but securities available-for-sale declined 2.8% QoQ to $226,785 thousand. Comprehensive income fell to $1,949 thousand from $5,766 thousand YoY due to a $249 thousand unrealized loss on securities.

• · Provision for credit losses released $76 thousand in Q1 2026 vs $10 thousand in Q1 2025.
• · EPS basic and diluted $0.63 in Q1 2026 vs $0.44 in Q1 2025.
• · Cash dividends paid $0.27 per share in both Q1 2026 and Q1 2025.
• · 3,493,256 common shares outstanding as of May 12, 2026.

13-05-2026

Unite Acquisition 2 Corp. reported a net loss of $72,013 for Q1 2026, up 17% YoY from $61,644, driven by higher general and administrative expenses of $63,876 (up 19% YoY). Cash balance declined to $417 from $886 at year-end 2025, while total liabilities rose to $525,699 (up 16% QoQ) amid increasing payables and notes; however, net cash used in operations improved slightly to $2,969 from $10,981 YoY. Stockholder's deficit widened to $525,282 from $453,269 QoQ.

• · Loss per common share: $0.014 (Q1 2026) vs. $0.012 (Q1 2025).
• · Note payable to stockholder increased to $92,500 from $90,000 QoQ.
• · Accrued interest on Lucius note: $46,923 (up from $38,786 QoQ).

13-05-2026

The Canary XRP ETF reported a significant decline in net assets to $264,767,022 as of March 31, 2026, down 18% from $322,819,725 at December 31, 2025, driven by a $94.7M unrealized depreciation in XRP holdings and a net decrease from operations of $95.3M. NAV per share fell 27% to $14.28 from $19.58, while shares outstanding increased 12% to 18,540,000 amid $38M in share sales, partially offsetting the losses with $37.3M net capital inflow. XRP investments dropped 18% in value to $264,883,295 despite a quantity increase to 197,214,584 tokens.

• · Sponsor fees for Q1 2026: $374,999.
• · 30,000 shares redeemed in January 2026 at average price of $22.87 per share.
• · Investments in securities at cost: $429,153,979 as of March 31, 2026.

13-05-2026

The Canary Marinade Solana ETF (SOLC) reported net assets of $1,145,618 as of March 31, 2026, down 40.5% from $1,926,808 at December 31, 2025, with NAV per share declining 32.0% to $16.37 from $24.09 amid significant unrealized depreciation of $539,756 on Solana holdings. While staking income provided $21,975 in net investment income, operations resulted in a net decrease of $551,958 due to realized losses of $34,177, and capital share transactions showed net outflows of $229,232 from redemptions exceeding sales. Shares outstanding fell 12.5% to 70,000 from 80,000.

• · Sponsor fees of $1,691 fully waived for the quarter ended March 31, 2026.
• · 20,000 shares redeemed in January 2026 at average price of $25.49 per share; no redemptions in February or March 2026.
• · Investments in Solana at cost: $1,854,598 at March 31, 2026 (vs. fair value $1,145,618); $2,096,032 at December 31, 2025 (vs. fair value $1,926,808).

13-05-2026

Tamboran Resources reported no revenue for the three months ended March 31, 2026, with net loss attributable to stockholders increasing 41% YoY to $9.4M from $6.7M, though the nine-month loss improved 9% to $24.2M from $26.7M. Total assets expanded 51% to $672M from $446M at June 30, 2025, supported by $110M in common stock proceeds and $55M NCI contributions, boosting cash and equivalents to $102M. However, operating cash use rose 17% to $27M over nine months, driven by $80M exploration payments and $112M total investing outflows.

• · Unproved properties increased to $465M from $342M.
• · Payments for exploration and evaluation: $79,739 thsd in 9 months 2026 vs $74,078 thsd 2025.
• · Net cash from financing activities: $194M in 9 months 2026 vs $48M 2025.
• · Foreign currency translation gain contributed to comprehensive income of $3.9M attrib to stockholders in Q3.

13-05-2026

AYTU BioPharma's Q3 FY2026 net revenue declined 33% YoY to $12,411 thousand from $18,452 thousand, with ADHD Portfolio down 41% to $9,093 thousand, Pediatric Portfolio down 70% to $921 thousand, offset partially by new EXXUA revenue of $2,397 thousand; for the nine months, revenue fell 19% to $41,464 thousand. The company reported a Q3 net loss of $5,618 thousand versus prior year profit of $3,994 thousand, and nine-month net loss of $14,237 thousand versus $6,256 thousand profit, with operating cash use improving to $1,125 thousand from $4,740 thousand. Stockholders' equity rose to $35,143 thousand from $18,966 thousand at June 30, 2025, boosted by warrant exercises and derivative reclassification.

• · Total current liabilities decreased to $59,972 thousand from $63,064 thousand at June 30, 2025.
• · Derivative warrant liabilities fell sharply to $2,182 thousand from $26,334 thousand.
• · Inventories declined to $7,460 thousand from $11,434 thousand, with finished goods down significantly.
• · Net cash used in operating activities for nine months improved to $1,125 thousand from $4,740 thousand.

13-05-2026

For Q1 2026, Aquestive Therapeutics reported revenues of $14,446, up 66% YoY from $8,720, with significant improvements in selling, general, and administrative expenses which fell 42% to $10,977. Net loss narrowed to $8,057 from $22,930 YoY, and loss per share improved to $(0.07) from $(0.24). However, the company continues to report operating losses of $4,204, cash used in operations increased usage to $14,806 from $23,400 but cash position declined to $110,734 from $121,169 at year-end amid ongoing burn.

• · Research and development expenses decreased 22% YoY to $4,204 from $5,361.
• · Net cash used for operating activities was $14,806 in Q1 2026 vs $23,400 in Q1 2025.
• · Stockholders’ deficit increased slightly to $(34,054) from $(33,662) at Dec 31, 2025.

13-05-2026

Grocery Outlet Holding Corp. reported net sales of $1,166,352 thousand for the 13 weeks ended April 4, 2026, up 3.6% YoY from $1,125,567 thousand, with perishable sales increasing 2.4% to $440,987 thousand and non-perishable up 4.4% to $725,365 thousand. However, a $158,000 thousand goodwill impairment, alongside higher SG&A expenses of $347,022 thousand (up 4.8% YoY), resulted in an operating loss of $178,014 thousand and net loss of $180,322 thousand, significantly worse than the prior year's $22,508 thousand and $23,317 thousand losses. Operating cash flow was $52,558 thousand, down 10.8% from $58,938 thousand YoY.

• · Goodwill decreased to $475,835 thousand from $633,835 thousand QoQ due to $158,000 thousand impairment.
• · Total stockholders' equity declined to $807,096 thousand from $983,663 thousand at January 3, 2026.
• · Property and equipment, net increased to $755,562 thousand from $742,961 thousand QoQ.
• · Restructuring charges decreased to $18,191 thousand from $33,875 thousand YoY.

13-05-2026

Skinvisible, Inc. reported flat revenues of $5,000 for Q1 2026 versus Q1 2025, with operating expenses declining 9.6% to $130,938, leading to a reduced net loss of $267,184 from $281,005 YoY. However, cash balances fell to $1,798 from $2,620 at December 31, 2025 (down 31.4% QoQ), total liabilities increased to $10,649,384 from $10,390,348 QoQ, and stockholders' deficit worsened to $10,529,965.

• · No cost of revenues or investing cash flows in Q1 2026.
• · No cash paid for interest or taxes in Q1 2026.
• · Patents and trademarks, net: $95,029 at March 31, 2026 (down from $100,036 at Dec 31, 2025).

13-05-2026

Snail, Inc. reported Q1 2026 revenues of $27,294,654, up 35.8% YoY from $20,110,872, with gross profit more than doubling to $11,656,441 from $5,847,527 and swinging to operating income of $2,040,343 from a $4,100,838 loss, resulting in net income of $2,134,556 versus a prior-year loss. Operating cash flow strengthened significantly to $10,207,831 from $764,549, boosting cash to $14,259,168. However, total assets declined 4.2% QoQ to $56,841,764 from $59,307,138, accounts receivable fell 26.5% QoQ to $9,206,357, and related party accounts payable rose to $21,648,949 from $20,067,013.

• · Accounts payable – related parties increased to $21,648,949 as of March 31, 2026 from $20,067,013 as of Dec 31, 2025.
• · Revolving loan reduced to $2,500,000 from $5,000,000 QoQ.
• · Weighted-average Class A shares basic: 9,036,135 (Q1 2026) vs 8,442,025 (Q1 2025).
• · Software license royalties – related parties: $6,333,981 (Q1 2026) vs $5,273,727 (Q1 2025).